Healthcare >> CEO Interviews >> June 2, 2003
DAVID G. ELSLEY is President and Chief Executive Officer of
Vasogen Inc. Over the past 10 years, Mr. Elsley has been
responsible for the scientific, clinical and commercial
development of Vasogen's immune modulation therapy. Since
becoming Vasogen's President in 1991 and Chief Executive Officer
in 1995, he has identified the commercial potential for new
therapies based on immune modulation for the treatment of
cardiovascular and other diseases characterized by chronic
inflammation. Through corporate development initiatives, Mr.
Elsley has increased the awareness of Vasogen's technology
amongst the medical and financial communities and has secured the
necessary resources to support the scientific and clinical
development of this promising therapeutic approach. He has
assembled a team of industry leaders with the requisite skill and
experience to successfully commercialize new healthcare
technologies. Prior to joining Vasogen, Mr. Elsley held marketing
and management positions with Seiko Epson Corporation and the
Hudson's Bay Company of Canada. Mr. Elsley holds a Master of
Business Administration degree from the Richard Ivey School of
Business, University of Western Ontario. Profile
Mr. Elsley: Vasogen has emerged as a leader in the research and
commercial development of immune modulation therapies targeting
chronic
